

Suzanne Nielsen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/163071/suzanne-nielsen-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144
papers

3,099
citations

29
h-index

50
g-index

160
ext. papers

3,930
ext. citations

4.5
avg, IF

5.74
L-index

#	Paper	IF	Citations
144	The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy.. <i>Substance Abuse and Rehabilitation</i> , 2022 , 13, 1-12	5.5	0
143	Infrequent detection of unintentional fentanyl use via urinalysis among people who regularly inject opioids in Sydney and Melbourne, Australia.. <i>Addiction</i> , 2022 ,	4.6	2
142	Comparing opioid types in the persistence of opioid use following surgical admission: a study protocol for a retrospective observational linkage study comparing tapentadol and oxycodone in Australia.. <i>BMJ Open</i> , 2022 , 12, e060151	3	
141	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain.. <i>International Journal of Drug Policy</i> , 2022 , 105, 103708	5.5	
140	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021 , 116, 1482-1494	4.6	1
139	Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a moral hazard associated with naloxone supply. <i>International Journal of Drug Policy</i> , 2021 , 100, 103513	5.5	4
138	Time to address addiction treatment inequality in hospital settings. <i>Lancet Public Health</i> , 2021 ,	22.4	1
137	Key considerations for the implementation of clinically focused Prescription Drug Monitoring Programs to avoid unintended consequences.. <i>International Journal of Drug Policy</i> , 2021 , 101, 103549	5.5	0
136	Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. <i>International Journal of Drug Policy</i> , 2021 , 99, 103472	5.5	0
135	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2021 , 100, 103492	5.5	2
134	Should we be routinely co-prescribing naloxone for patients on long term opioids?. <i>Medical Journal of Australia</i> , 2021 , 214, 403-404.e1	4	0
133	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. <i>JAMA Network Open</i> , 2021 , 4, e213059	10.4	2
132	What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy. <i>International Journal of Clinical Pharmacy</i> , 2021 , 43, 420-429	2.3	1
131	Community pharmacists' preparedness to intervene with concerns around prescription opioids: findings from a nationally representative survey. <i>International Journal of Clinical Pharmacy</i> , 2021 , 43, 411-419	2.3	1
130	Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2021 , 40, 98-108	3.2	1
129	Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia. <i>International Journal of Drug Policy</i> , 2021 , 90, 103061	5.5	3
128	Characteristics of oxycodone-related ambulance attendances: analysis of temporal trends and the effect of reformulation in Victoria, Australia from 2013 to 2018. <i>Addiction</i> , 2021 , 116, 2233-2241	4.6	

127	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001-2018: Findings from the OATS retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2021 , 218, 108354	4.9	1
126	Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia. <i>Harm Reduction Journal</i> , 2021 , 18, 20	4.6	12
125	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021 , 219, 108464	4.9	2
124	Pharmaceutical opioid poisonings in Victoria, Australia: Rates and characteristics of a decade of emergency department presentations among nine pharmaceutical opioids. <i>Addiction</i> , 2021 ,	4.6	2
123	How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2021 , 228, 109090	4.9	4
122	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3092-3104	3.8	2
121	Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: A cohort study and nested crossover-cohort analysis. <i>Drug and Alcohol Dependence</i> , 2020 , 217, 108343	4.9	2
120	Validity and Reliability of the Computer-Administered Routine Opioid Outcome Monitoring (ROOM) Tool. <i>Pain Medicine</i> , 2020 , 21, 3645-3654	2.8	0
119	Alprazolam use among a sample of Australians who inject drugs: Trends up to six years post regulatory changes. <i>International Journal of Drug Policy</i> , 2020 , 79, 102721	5.5	3
118	Unintended consequences of using real time prescription monitoring systems. <i>Medical Journal of Australia</i> , 2020 , 213, 142-142.e1	4	2
117	A systematic review of opioid overdose interventions delivered within emergency departments. <i>Drug and Alcohol Dependence</i> , 2020 , 213, 108009	4.9	14
116	Community pharmacy naloxone supply, before and after rescheduling as an over-the-counter drug: sales and prescriptions data, 2014-2018. <i>Medical Journal of Australia</i> , 2020 , 212, 314-320	4	3
115	Efficacy of cannabinoids for treating paediatric spasticity in cerebral palsy or traumatic brain injury: what is the evidence?. <i>Developmental Medicine and Child Neurology</i> , 2020 , 62, 1007	3.3	0
114	Commentary on Cairns et al. (2020): Codeine rescheduling-where to from here?. <i>Addiction</i> , 2020 , 115, 460-461	4.6	0
113	Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study. <i>Research in Social and Administrative Pharmacy</i> , 2020 , 16, 1694-1701	2.9	4
112	Etizolam: A rapid review on pharmacology, non-medical use and harms. <i>Drug and Alcohol Review</i> , 2020 , 39, 330-336	3.2	21
111	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020 , 21, e79-e88	2.8	4
110	Impact of Removing Nonprescription Codeine in Australia: Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2020 , 9, e15540	2	0

109	Opioid agonist treatment in the time of fentanyl: What can we learn from emerging evidence?. <i>Drug and Alcohol Review</i> , 2020 , 39, 203-204	3.2	2
108	Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives. <i>Drug and Alcohol Review</i> , 2020 , 39, 55-65	3.2	4
107	Correlates of indicators of potential extra-medical opioid use in people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Review</i> , 2020 , 39, 128-134	3.2	3
106	The price and mark up of pharmaceutical drugs supplied on the black market. <i>International Journal of Drug Policy</i> , 2020 , 76, 102626	5.5	2
105	Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Victoria, Australia from 2013 to 2018. <i>Addiction</i> , 2020 , 115, 1075-1087	4.6	10
104	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020 , 115, 1295-1305	4.6	29
103	Validation of the OWLS, a Screening Tool for Measuring Prescription Opioid Use Disorder in Primary Care. <i>Pain Medicine</i> , 2020 , 21, 2757-2764	2.8	0
102	Extreme personal stress and a lot of pain: Exploring the physical, mental and social contexts of extramedical pharmaceutical opioid use in Australian paramedic case descriptions. <i>Drug and Alcohol Review</i> , 2020 , 39, 870-878	3.2	3
101	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EclinicalMedicine</i> , 2020 , 28, 100592	11.3	3
100	Comparing rates and characteristics of emergency department presentations related to pharmaceutical opioid poisoning in Australia: a study protocol for a retrospective observational study. <i>BMJ Open</i> , 2020 , 10, e038979	3	1
99	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020 , 10, e034389	3	6
98	Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia. <i>Journal of Psychiatric Research</i> , 2020 , 130, 435-440	5.2	3
97	Recent trends in heroin and pharmaceutical opioid-related harms in Victoria, Australia up to 2018. <i>Addiction</i> , 2020 , 115, 261-269	4.6	13
96	Cannabinoids for the treatment of spasticity. <i>Developmental Medicine and Child Neurology</i> , 2019 , 61, 631-638	3.3	9
95	Drug sourcing and motivations among a sample of people involved in the supply of pharmaceutical drugs in Australia. <i>International Journal of Drug Policy</i> , 2019 , 66, 38-47	5.5	8
94	Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study. <i>BMJ Open</i> , 2019 , 9, e029170	3	9
93	Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study. <i>International Journal of Drug Policy</i> , 2019 , 69, 46-52	5.5	17
92	How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities. <i>Research in Social and Administrative Pharmacy</i> , 2019 , 15, 1014-1020	2.9	10

91	What factors contributed to the misconduct of health practitioners? An analysis of Australian cases involving the diversion and supply of pharmaceutical drugs for non-medical use between 2010 and 2016. <i>Drug and Alcohol Review</i> , 2019 , 38, 366-376	3.2	4
90	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019 , 20, 2450-2458	2.8	7
89	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019 , 20, 758-769	2.8	7
88	Estimating Centre for Disease Control and Prevention-defined overdose risk in people prescribed opioids for chronic non-cancer pain: implications for take-home naloxone provision. <i>Internal Medicine Journal</i> , 2019 , 49, 1054-1055	1.6	7
87	Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine. <i>Drugs</i> , 2019 , 79, 1395-1418	12.1	47
86	Changes in Australian prescription opioid use following codeine rescheduling: A retrospective study using pharmaceutical benefits data. <i>International Journal of Drug Policy</i> , 2019 , 74, 170-173	5.5	14
85	A protocol for a discrete choice experiment: understanding patient medicine preferences for managing chronic non-cancer pain. <i>BMJ Open</i> , 2019 , 9, e027153	3	3
84	Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol. <i>Research in Social and Administrative Pharmacy</i> , 2019 , 15, 1047-1055	2.9	9
83	Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019 , 269, 135-144	5.1	20
82	The source and diversion of pharmaceutical drugs for non-medical use: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2018 , 186, 242-256	4.9	47
81	The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. <i>Current Neurology and Neuroscience Reports</i> , 2018 , 18, 8	6.6	71
80	Commentary on McDonald et al. (2018): Intranasal naloxone-from the laboratory to the real world. <i>Addiction</i> , 2018 , 113, 494-495	4.6	
79	Commentary on Chang et al. (2018): Assessing prescribing volume and patient risk-implementation considerations. <i>Addiction</i> , 2018 , 113, 687-688	4.6	
78	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. <i>Pain Medicine</i> , 2018 , 19, 533-540	2.8	23
77	Attitudes in Australia on the upscheduling of over-the-counter codeine to a prescription-only medication. <i>Drug and Alcohol Review</i> , 2018 , 37, 257-261	3.2	14
76	A nationwide study of the extent and factors associated with fentanyl use in Australia. <i>Research in Social and Administrative Pharmacy</i> , 2018 , 14, 303-308	2.9	5
75	Perceived stigma and social support in treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018 , 37, 262-272	3.2	20
74	Naloxone rescheduling in Australia: Processes, implementation and challenges with supply of naloxone as a pharmacist only over-the-counter medicine. <i>Drug and Alcohol Review</i> , 2018 , 37, 450-453	3.2	10

73	What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. <i>International Review of Psychiatry</i> , 2018 , 30, 91-106	3.6	16
72	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018 , 37, 887-896	3.2	3
71	Urine drug screening for early detection of unwitting use of fentanyl and its analogues among people who inject heroin in Sydney, Australia. <i>Drug and Alcohol Review</i> , 2018 , 37, 847-850	3.2	13
70	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018 , 8, e025204 ³		16
69	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. <i>Current Addiction Reports</i> , 2018 , 5, 464-472	3.9	8
68	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. <i>Pain</i> , 2018 , 159, 1932-1954 ⁸		209
67	Identifying and treating codeine dependence: a systematic review. <i>Medical Journal of Australia</i> , 2018 , 208, 451-461	4	31
66	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health</i> , 2018 , 3, e341-e350	22.4	117
65	Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. <i>Drug and Alcohol Review</i> , 2017 , 36, 311-316	3.2	3
64	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 587-591	2.6	28
63	Benzodiazepine use of community-based violent offenders: a preliminary investigation. <i>Journal of Substance Use</i> , 2017 , 22, 295-303	0.8	2
62	Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 967-968	27.4	46
61	A mapping review of take-home naloxone for people released from correctional settings. <i>International Journal of Drug Policy</i> , 2017 , 46, 7-16	5.5	15
60	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. <i>Neuropsychopharmacology</i> , 2017 , 42, 1752-1765	8.7	132
59	Stigma and Social Support in Pharmaceutical Opioid Treatment Populations: a Scoping Review. <i>International Journal of Mental Health and Addiction</i> , 2017 , 15, 452-469	8.8	24
58	Benzodiazepines. <i>Current Topics in Behavioral Neurosciences</i> , 2017 , 34, 141-159	3.4	9
57	Over-the-Counter Codeine-from Therapeutic Use to Dependence, and the Grey Areas in Between. <i>Current Topics in Behavioral Neurosciences</i> , 2017 , 34, 59-75	3.4	20
56	Community use of naloxone for opioid overdose. <i>Australian Prescriber</i> , 2017 , 40, 137-140	1.4	6

55	Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. <i>Addiction</i> , 2016 , 111, 2177-2186	4.6	49
54	Alprazolam use and related harm among opioid substitution treatment clients - 12 months follow up after regulatory rescheduling. <i>International Journal of Drug Policy</i> , 2016 , 36, 104-11	5.5	15
53	Health service utilisation by people living with chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. <i>Australian Health Review</i> , 2016 , 40, 490-499	1.8	3
52	Opioid agonist treatment for pharmaceutical opioid dependent people. <i>The Cochrane Library</i> , 2016 , CD011117	3.1	112
51	An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 469-94	2.8	29
50	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. <i>Drug and Alcohol Dependence</i> , 2016 , 162, 79-87	4.9	29
49	Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016 , 35, 70-75	3.2	5
48	What is known about community pharmacy supply of naloxone? A scoping review. <i>International Journal of Drug Policy</i> , 2016 , 32, 24-33	5.5	36
47	Geographic Variation in Health Service Use and Perceived Access Barriers for Australian Adults with Chronic Non-Cancer Pain Receiving Opioid Therapy. <i>Pain Medicine</i> , 2016 , 17, 2003-2016	2.8	6
46	Prescribing and Dispensing of Benzodiazepines: Implications for Dependence and Misuse 2016 , 283-292		
45	Sleep Quality Among People Living With Chronic Noncancer Pain: Findings From the Pain and Opioids IN Treatment (POINT) Cohort. <i>Clinical Journal of Pain</i> , 2016 , 32, 380-7	3.5	8
44	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. <i>Pain</i> , 2016 , 157, 1489-1498	8	25
43	The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 521-38	2.6	50
42	A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 733-7	2.6	192
41	Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. <i>Drug and Alcohol Dependence</i> , 2016 , 159, 42-52	4.9	22
40	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016 , 166, 125-33	4.9	7
39	Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain. <i>Journal of Affective Disorders</i> , 2015 , 184, 72-80	6.6	24
38	The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. <i>Pain</i> , 2015 , 156, 231-242	8	85

37	Comparing treatment-seeking codeine users and strong opioid users: Findings from a novel case series. <i>Drug and Alcohol Review</i> , 2015 , 34, 304-11	3.2	19
36	Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users. <i>Journal of Substance Abuse Treatment</i> , 2015 , 48, 70-6	4.2	22
35	Prescription drug abuse: from epidemiology to public policy. <i>Journal of Substance Abuse Treatment</i> , 2015 , 48, 1-7	4.2	68
34	Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. <i>Drug and Alcohol Review</i> , 2015 , 34, 623-9	3.2	5
33	Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. <i>American Journal on Addictions</i> , 2015 , 24, 667-75	3.7	16
32	Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. <i>Medical Journal of Australia</i> , 2015 , 203, 299	4	54
31	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. <i>Pain Medicine</i> , 2015 , 16, 1745-58	2.8	58
30	Benzodiazepine use among chronic pain patients prescribed opioids: associations with pain, physical and mental health, and health service utilization. <i>Pain Medicine</i> , 2015 , 16, 356-66	2.8	77
29	Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. <i>Lancet Psychiatry</i> , 2015 , 2, 314-22 ²³⁻³		37
28	Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study. <i>BMC Pharmacology & Toxicology</i> , 2014 , 15, 17	2.6	34
27	Opioid agonist treatment for pharmaceutical opioid dependent people 2014 ,		3
26	The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. <i>American Journal on Addictions</i> , 2014 , 23, 343-8	3.7	14
25	Diversion of prescribed opioids by people living with chronic pain: results from an Australian community sample. <i>Drug and Alcohol Review</i> , 2014 , 33, 27-32	3.2	11
24	A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes. <i>Drug and Alcohol Review</i> , 2013 , 32, 88-95	3.2	15
23	Correlates of pain in an in-treatment sample of opioid-dependent people. <i>Drug and Alcohol Review</i> , 2013 , 32, 489-94	3.2	6
22	Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. <i>Contemporary Clinical Trials</i> , 2013 , 34, 196-204	2.3	21
21	A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. <i>Journal of Addiction Medicine</i> , 2013 , 7, 33-8	3.8	35
20	Opportunities and challenges: over-the-counter codeine supply from the codeine consumer's perspective. <i>International Journal of Pharmacy Practice</i> , 2013 , 21, 161-8	1.7	29

19	A cross-sectional analysis of over-the-counter codeine use among an Australian sample of people who regularly inject drugs. <i>Drug and Alcohol Review</i> , 2013 , 32, 574-81	3.2	12
18	Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). <i>Journal of Studies on Alcohol and Drugs</i> , 2013 , 74, 605-13	1.9	86
17	The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. <i>Medical Journal of Australia</i> , 2013 , 199, 696-9	4	19
16	Recent increase in detection of alprazolam in Victorian heroin-related deaths. <i>Medical Journal of Australia</i> , 2013 , 198, 206-9	4	24
15	Comparing buprenorphine induction experience with heroin and prescription opioid users. <i>Journal of Substance Abuse Treatment</i> , 2012 , 43, 285-90	4.2	17
14	Pharmaceutical opioid analgesic and heroin dependence: how do treatment-seeking clients differ in Australia?. <i>Drug and Alcohol Review</i> , 2011 , 30, 291-9	3.2	25
13	Selective review and commentary on emerging pharmacotherapies for opioid addiction. <i>Substance Abuse and Rehabilitation</i> , 2011 , 2, 181-8	5.5	11
12	Benzodiazepines - Their role in aggression and why GPs should prescribe with caution. <i>Australian Family Physician</i> , 2011 , 40, 862-5		20
11	Characteristics of a nontreatment-seeking sample of over-the-counter codeine users: implications for intervention and prevention. <i>Journal of Opioid Management</i> , 2011 , 7, 363-70	0.8	8
10	Benzodiazepines, methadone and buprenorphine: interactions and clinical management. <i>American Journal on Addictions</i> , 2010 , 19, 59-72	3.7	79
9	Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases. <i>Medical Journal of Australia</i> , 2010 , 193, 294-6	4	110
8	The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence. <i>Experimental and Clinical Psychopharmacology</i> , 2010 , 18, 489-97	3.2	25
7	Prescription drug misuse: is technology friend or foe?. <i>Drug and Alcohol Review</i> , 2009 , 28, 81-6	3.2	33
6	The use of sublingual buprenorphine-naloxone for reversing heroin overdose: a high-risk strategy that should not be recommended. <i>Addiction</i> , 2008 , 103, 2065-6	4.6	5
5	Methadone- and buprenorphine-related ambulance attendances: a population-based indicator of adverse events. <i>Journal of Substance Abuse Treatment</i> , 2008 , 35, 457-61	4.2	10
4	Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. <i>Addiction</i> , 2007 , 102, 616-22	4.6	69
3	Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. <i>Drug and Alcohol Review</i> , 2007 , 26, 143-51	3.2	22
2	The effect of buprenorphine and benzodiazepines on respiration in the rat. <i>Drug and Alcohol Dependence</i> , 2005 , 79, 95-101	4.9	33

1 Crushing buprenorphine tablets. *Drug and Alcohol Review*, **2003**, 22, 471-2

3.2 5